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Abstract 1 
EBV infection is ubiquitous in humans, but the majority of infections have an asymptomatic or self-2 
limiting clinical course.  Rarely, individuals may develop a pathological EBV infection with a variety of 3 
life threatening complications (including haemophagocytosis and malignancy) and others develop 4 
asymptomatic chronic EBV viraemia.  Although an impaired ability to control EBV infection has long 5 
been recognised as a hallmark of severe T-cell immunodeficiency, the advent of next generation 6 
sequencing has identified a series of Primary Immunodeficiencies in which EBV-related pathology is 7 
the dominant feature.  Chronic active EBV infection is defined as chronic EBV viraemia associated 8 
with systemic lymphoproliferative disease, in the absence of immunodeficiency. Descriptions of 9 
larger cohorts of patients with chronic active EBV in recent years have significantly advanced our 10 
understanding of this clinical syndrome.  In this review we summarise the current understanding of 11 
the pathophysiology and natural history of these diseases and clinical syndromes, and discuss 12 
approaches to the investigation and treatment of severe or atypical EBV infection. 13 
  14 
Introduction 1 
Epstein Barr Virus is a γ-herpesvirus characterised by restricted infectious specificity to humans, and 2 
latent infection in B lymphocytes.  Primary infection with EBV typically occurs in childhood as a 3 
symptomless or mild infection, with early infection seen in a higher proportion of the population of 4 
low income, compared to high income countries (Cohen 2000; Pariente et al. 2007; Hjalgrim, Friborg, 5 
and Melbye 2007)(e.g. 58.9% of Zambian infants aged 12 months are EBV seropositive (Minhas et al. 6 
2010) compared to 7.1% of infants in a Swedish infants (Hesla et al. 2013)).  By age 30, >95% of 7 
adults in Europe and North America are seropositive (Cohen 2000; Pariente et al. 2007; Pembrey et 8 
al. 2013).  Primary EBV infection in adolescence or adulthood leads to a 25-70% risk of developing a 9 
symptomatic EBV infection, known as infectious mononucleosis (IM) (Higgins et al. 2007; McAulay et 10 
al. 2007).  This is characterised by pharyngitis, benign lymphoproliferation, fever and malaise, and 11 
symptoms last up to 6 weeks duration in the majority of patients. 12 
Following primary infection, EBV persists within resting memory B-cells (Miyashita et al. 1997) with 13 
low immunogenicity (Babcock, Hochberg, and Thorley-Lawson 2000), allowing a life-long infection to 14 
be established, which the immune system cannot clear. 15 
EBV Life cycle 16 
EBV has a biphasic life cycle, divided into lytic and latent gene expression programmes (Tsurumi, 17 
Fujita, and Kudoh 2005)(figure 1).  The lytic gene expression programmes allow EBV to productively 18 
infect new cells and new hosts, while establishment of latency is vital to allow life-long persistence 19 
of the virus within infected cells, through a highly restricted gene expression profile in order to avoid 20 
immune surveillance (Young, Arrand, and Murray 2007). 21 
EBV is naturally transmitted through saliva (Gerber et al. 1972), and the first cells thought to be 22 
infected by EBV during primary infection are oral epithelial cells and naïve Bcells (Balfour et al. 23 
2013).  During the lytic cycle, EBV infection is followed by the induction of two immediate early 24 
proteins (Rta and EB1) which act as transcriptional activators for a wide range of proteins and viral 25 
RNAs involved in viral DNA replication or viral structural proteins.  True latency (type 0), where cells 26 
express no EBV protein or RNA, but retain senescent episomal EBV DNA, is subsequently established 27 
in the resting B memory pool.  Although this transition to latency is not fully understood, a model 28 
proposing EBV exploitation of the physiological B-cell differentiation pathway is helpful when 29 
considering the pathological states following EBV infection (Thorley-Lawson et al. 2013)).  In this, 30 
infected naïve B-cells enter a proliferative phase during which they express the full range of latent 31 
EBV proteins and viral RNAs (latency type 3, equivalent of in vitro derived B lymphoblastoid cell 32 
lines).  A proportion of these cells differentiate further into latency type 2 within the oropharyngeal 33 
germinal centres in response to EBV-specific T follicular helper cells, resulting in restriction of EBV 1 
protein expression to EBV nuclear antigen (EBNA) 1, latent membrane protein (LMP) 1 and 2 2 
proteins only.  Further differentiation results in the release of latency type 0 resting B memory cells 3 
into the circulation.  Sporadically, as these cells recirculate through the oropharynx, a proportion 4 
switch from the immunologically silent latent infection, to the productive lytic cycle.   5 
The virus is shed at particularly high levels from four-six weeks after initial infection (Dunmire et al. 6 
2015), reducing as the infected individual convalesces.  Low-level shedding of EBV in saliva continues 7 
sporadically for life (Hadinoto et al. 2009), as cycles of lytic reactivation within B-cells and 8 
oropharyngeal epithelial cells are interrupted by immunological control, leading to a return to latent 9 
infection (Taylor et al. 2015). 10 
From epidemiological studies and in vitro work, a number of factors have been identified which may 11 
drive the change from a latent to a lytic gene expression profile in EBV infected cells (Kenney 2007). 12 
In latently infected individuals it has been shown that stress (e.g. sleep deprivation) leads to 13 
increased EBV genome production (Uchakin et al. 2011; Mehta et al. 2000), and EBV lytic 14 
transcription factor BZLF1 may be induced by glucocorticoids (Yang et al. 2010), demonstrating a link 15 
between the host environment and permissivity of viral reactivation.  Suppression of T-cell immunity 16 
(e.g. after organ transplantation) is also strongly associated with EBV reactivation (Hiwarkar et al. 17 
2013), as is concurrent infection with some other pathogens, such as Group A Streptococcus (Ueda 18 
et al. 2014) and malaria (Plasmodium falciparum) (Moormann et al. 2005). 19 
Immune Response to EBV infection 20 
Primary EBV infection in the immunocompetent host leads to distinct antibody responses.  The EBV 21 
proteins expressed during lytic infection, such as Viral Capsid Antigen (VCA) and Immediate Early 22 
Antigen (EA), are often highly immunogenic with antibodies to VCA detectable up to a week before 23 
the onset of IM symptoms.  Antibody responses to latent proteins are delayed, with anti-EBNA2 IgG 24 
appearing at the height of symptoms, and the anti-EBNA1 IgG response developing from 3 months 25 
post-infection.  The hallmark of primary EBV infection is detectable IgM and rising IgG VCA antibody 26 
responses, in the absence of an EBNA1 IgG response (Taylor et al. 2015).  In a study of individuals 27 
who had recently experienced IM, 88% of individuals were positive for VCA-IgM, 100% were positive 28 
for VCA-IgG, and 96% were positive for EBNA1-IgG (Balfour et al. 2013).   29 
Studies of individuals in the early stages of EBV seroconversion show an expansion in peripheral 30 
Natural Killer (NK) cells at the point of symptom onset, 4-6 weeks after initial infection (Balfour et al. 31 
2013).  Although NK-cell numbers correlate with virus load in the peripheral blood, they 32 
demonstrate little evidence of increased activation, as measured by granzyme B levels.  CD8+ T-cell 33 
expansion follows the same pattern with a dramatic proliferation of lytic antigen specific CD8+ T-1 
cells during IM, and a much smaller response to latent antigens.  Onset of symptoms correlates 2 
much more closely with CD8+ cell expansion, than with EBV viral load, supporting a model of IM as 3 
an immunopathic disease (Balfour et al. 2013).  EBV-specific CD8+ T-cells also develop during 4 
asymptomatic EBV infection, however the total CD8+ T-cell counts remain within the normal range, 5 
suggesting activated CD8+ T-cell over-proliferation is associated with symptomatic disease 6 
(Jayasooriya et al. 2015).  CD4+ T-cell expansion also occurs during IM, although this is less dramatic 7 
than the CD8+ response. The CD4+ response is predominantly towards latent EBV antigens and 8 
demonstrates a wider distribution of epitope responses.  A detailed review the immune response to 9 
EBV infection can be found elsewhere (Taylor et al. 2015).   10 
Pathological Responses to EBV infection 11 
Although the majority of individuals infected with EBV have an asymptomatic or self-limiting clinical 12 
course, there is a broad range of pathological responses to infection, encompassing prolonged fever 13 
and lymphoproliferation (severe IM), haemophagocytic lymphohistiocytosis, autoimmunity and 14 
malignancy.  These states arise from unregulated cytotoxic and inflammatory responses to EBV 15 
infected B-cells, impaired T-cell or NK-cell immune surveillance of EBV infected cells, EBV infection in 16 
aberrant (non-B) cells or as yet undefined mechanisms.  Each of these pathological mechanisms can 17 
be in seen in immunodeficient patients (primary or secondary) or apparently normal hosts.   18 
Haemophagocytic lymphohistiocytosis (HLH) 19 
HLH is a severe, life-threatening immunodysregulatory disorder resulting from the uncontrolled 20 
activation and proliferation of T-cells and macrophages, which causes excessive production of 21 
cytokines, hyperinflammation and tissue damage.  It is classified as either primary HLH, when a 22 
family history of the disorder or identified genetic defect is present, or secondary HLH, associated 23 
with infection, rheumatological disorders (often termed macrophage activation syndrome) or 24 
malignancy.  Increasingly, HLH is also recognised as a complication of more “classical” primary 25 
immunuodeficiencies (PIDs) (Bode et al. 2015).  EBV is an important infectious trigger for both 26 
primary and secondary HLH.  The causes and investigation of primary HLH, and PID-associated HLH 27 
are summarised in Table 1. 28 
Regardless of the underlying cause, the clinical features of HLH are similar.  Clinical manifestations 29 
include prolonged fever, hepatosplenomegaly, hepatitis, cytopenias, coagulopathy, rashes and 30 
neurological symptoms.  The Histiocyte Society has developed diagnostic criteria for HLH, based on 31 
both clinical and laboratory findings (Table 2), to help guide the initiation of therapy. 32 
In the normal setting, cytotoxic T lymphocytes (CTLs) and NK-cells, once in contact with a virally 1 
infected cell, respond by forming an immunological synapse with the target cell, followed by 2 
granule-mediated cytotoxicity.  This not only clears the virally infected cells but regulates the 3 
inflammatory response by removing antigenic stimulus.  Familial HLH results from impaired granule-4 
dependent cytotoxicity, resulting in impaired target cell death, continued stimulation of cytotoxic 5 
cells and ongoing production of inflammatory cytokines.  The clinical features of HLH are a 6 
consequence of the resultant uncontrolled macrophage activation and histiocytic transformation 7 
(Jordan et al. 2004). 8 
Standard of care treatment remains established, highly immunosuppressive, chemotherapeutic 9 
protocols (Henter et al. 2007).  Alternative and salvage therapies, including the use of anti-10 
thymocyte globulin (ATG) and monoclonal antibodies are reviewed elsewhere (Jordan et al. 2011; 11 
Mahlaoui et al. 2007).  Supportive care, particularly to prevent and treat infection is critical, and in 12 
EBV-HLH, removal of the infectious trigger with multiple courses of Rituximab is essential 13 
(Chellapandian et al. 2013). 14 
Following induction therapy patients with primary HLH should proceed urgently to Haematopoietic 15 
Stem Cell transplant (HSCT).  Long term management of secondary EBV-HLH is more difficult; 16 
however our practice is to progress to HSCT in patients with relapsing HLH or HLH associated with 17 
CAEBV (see below), even in the absence of a defined genetic aetiology.  It is critical to achieve 18 
remission prior to HSCT as the outcome in patients with active HLH is significantly worse.  The 19 
introduction of reduced intensity conditioning (RIC) regimes has improved the outlook for patients 20 
with primary HLH affording 3-year survival rates of 92% compared to 43% when myeloablative 21 
conditioning is used (Marsh, Vaughn, et al. 2010). 22 
Chronic Active EBV (CAEBV) 23 
Chronic Active EBV (CAEBV) was originally used to describe patients with chronic or recurrent 24 
infectious mononucleosis (Straus 1988).  It is now defined as EBV related illness lasting greater than 25 
3 months, associated with systemic EBV positive lymphoproliferative disease (LPD) (with elevated 26 
EBV DNA/RNA in affected tissues), and high level EBV viraemia or increased anti-VCA IgG titre, in the 27 
absence of defined primary or secondary immunodeficiency (Cohen et al. 2011; Kimura et al. 2012; 28 
Okano et al. 2005) (see table 2).  CAEBV has been most commonly described in East Asia where the 29 
proliferating cells are usually T- or NK-cells (Kimura et al. 2012).  This clinically heterozygous 30 
condition has overlap with two cutaneous syndromes – Hydroa Vacciniforme-like lymphoma (a 31 
recurrent vesiculopapular eruption usually caused by an EBV infected γδT-cell infiltration) and 32 
mosquito bite sensitivity associated with EBV positive lymphoproliferation (usually NK-cells) (Kimura, 33 
Kawada, and Ito 2013) (see figure 2).  In Western countries, CAEBV is rarer but usually associated 1 
with B-cell proliferation (Cohen et al. 2011).  In all of these conditions the lymphocyte, and EBV 2 
clonality may be monoclonal, oligoclonal or polyclonal (Kimura et al. 2012). 3 
Clinically, CAEBV has an aggressive course, with complications ranging from progression to HLH 4 
and/or lymphoma, disseminated intravascular coagulopathy, coronary artery aneurysms, CNS 5 
disease, myocarditis, pneumonitis and gastrointestinal perforation (Kimura et al. 2012; Cohen et al. 6 
2011).  In the largest series of EBV-associated T/NK-cell LPD, 108 Japanese   patients  demonstrated 7 
44% survival at a median follow up of 46 months (range 1 month – 21 years).  Patients with isolated 8 
cutaneous disease appear to have a better prognosis, and those with CD4+ T-cells as the EBV 9 
infected proliferative cell, do worse (Kimura et al. 2012).  Complications and prognosis for CAEBV 10 
with B-cell lymphoproliferation in the US seems to be similar, although interestingly 42% of these 11 
patients developed progressive hypogammaglobulinaemia and B-cell lymphopenia (even in the 12 
absences of rituximab therapy) (Cohen et al. 2011). 13 
CAEBV patients have significantly higher loads of EBV DNA in mononuclear cells compared to 14 
patients with IM (Xing et al. 2013).  Characteristically, patients have very high IgG antibody titres to 15 
EBV early antigen (EA) and VCA, but lack an IgG response to EBNA1 (Kimura et al. 2003), however, 16 
this pattern may be absent in up to 50% of patients and is therefore of limited diagnostic value.  The 17 
pathophysiology of CAEBV is poorly understood.  Despite the above antibody pattern being 18 
suggestive of a predominance of EBV lytic cycle infection, T and NK-cells demonstrate EBV infection 19 
in type 2 latency (Kimura et al. 2005).  CAEBV patients have a hyperinflammatory state with cytokine 20 
profiles (raised IL-1β, IL10, IFNγ) similar to patients with familial HLH (Ohga et al. 2001), suggesting 21 
an overlapping pathophysiology, with impaired removal of EBV infected T/NK-cells driving a local 22 
inflammatory response in infiltrated tissues, and a resultant pro-oncogenic and haemophagocytic 23 
environment (Rickinson 2014). 24 
EBV-positive systemic T-cell lymphoproliferative disease (STLPD) is a lymphoma of activated αβ T-25 
cells.  It usually develops following acute EBV infection, but can also arise as a malignant progression 26 
from CAEBV (Kimura, Kawada, and Ito 2013).  By definition this is a systemic illness caused by clonal 27 
proliferation of EBV infected T-cells (Quintanilla-Martinez, Kimura, and Jaffe 2008).  It almost 28 
invariably is associated with haemophagocytosis, and as the proliferating cells rarely show evidence 29 
of atypica, the differentiation from HLH or CAEBV is often difficult.  It is perhaps best thought of as 30 
the common neoplastic path of lymphoid proliferation in both HLH and CAEBV (Hong et al. 2013).. 31 
Treatment of CAEBV and STLPD remains unsatisfactory, with most patients treated according to their 32 
predominant clinical syndrome (HLH or lymphoma).  Rituximab, antiviral and chemotherapeutic 33 
drugs may have a role in stabilising early disease in occasional patients, but any clinical benefit is 1 
rarely sustained.  Results of early HSCT with RIC are encouraging, suggesting that conservative 2 
therapy should be reserved for patients with isolated cutaneous disease and easily controlled 3 
inflammation (Kimura et al. 2012; Cohen et al. 2011; Kawa et al. 2011). 4 
EBV driven malignancy and autoimmunity 5 
EBV-driven malignancy is seen in both immunocompentent and immunodeficient patients, with 6 
malignant transformation of lymphoid cells (T-, B- and NK-cells), and non-haematopoeitic cells 7 
(Figure 2).  Pathophysiology is multifactorial with the following being key pathogenic processes; (1) 8 
loss of immune surveillance / EBV-mediate immune evasion, (2) EBV infection induced growth factor 9 
and cytokine production, (3) EBV oncogene expression (particularly LMP1 and LMP2A) and (4) 10 
genetic / epigenetic alteration of the host genome.  The relative importance of each of these 11 
mechanisms varies for each individual malignancy (Murata, Sato, and Kimura 2014; Rickinson 2014; 12 
Taylor et al. 2015).   13 
EBV has also been implicated in the pathophysiology of autoimmunity, best characterised by 14 
associations with multiple sclerosis and systemic lupus erythematosis (Taylor et al. 2015; Thacker, 15 
Mirzaei, and Ascherio 2006) 16 
Common human genetic variation in EBV infection and immunity 17 
Susceptibility to EBV infection and disease may be described as a spectrum.  At one end lie rare 18 
monogenic mutations with large effects (Houldcroft and Kellam 2015), and at the other end are 19 
common polymorphisms with small effects, leading to subtle changes in risk of, and response to, 20 
infection.  In the middle is a less well defined category of low-frequency variants which are 21 
associated with disease phenotypes, but are also found in apparently healthy individuals (Manso et 22 
al. 2014), with no clear impact on gene function. 23 
Genome-wide association studies (GWAS) have identified a number of common genetic variants 24 
underlying population response to EBV infection.  Individuals vary in their antibody titres to EBNAs in 25 
a heritable manner.  A series of GWAS have identified single nucleotide polymorphisms (SNPs) within 26 
HLA class II genes as important for antibody response to EBV, specifically IgG antibodies to EBNA1 27 
(Hammer et al. 2015; Pedergnana et al. 2014; Rubicz et al. 2013).  Pederagna and Rubicz identified a 28 
cluster of SNPs near HLA-DRA, (although it was unclear which SNP drove the relationship with EBNA1 29 
IgG titres), and Hammer et al identified HLA-DRB1*07:01 as associated with lower anti-EBNA-1 IgG 30 
titres (beta: −0.17).  Candidate gene studies have also associated anti-VCA IgA and IgG titres to 31 
variants in a number of genes (Houldcroft and Kellam, 2015), but these variants have yet to be 32 
validated by the more agnostic GWAS approach 33 
This approach has also suggested variants within the HLA class 1 system as being important for 1 
susceptibility to EBV infection (Durovic et al. 2013), and risk of symptomatic infection (IM versus 2 
silent seroconversion) (McAulay et al. 2007).  Evidence from epidemiological studies further 3 
supports a common genetic basis for infectious mononucleosis susceptibility, as studies of IM risk in 4 
twins (Hwang et al. 2012) demonstrate that monozygotic twins have twice the relative risk of 5 
concordance for symptomatic IM compared to dizygotic twins.  Similarly, first degree relatives 6 
(Rostgaard, Wohlfahrt, and Hjalgrim 2014) show a heritable component of IM risk, based on studies 7 
of individuals hospitalised with severe IM, with rate ratios of IM increasing as genetic relatedness 8 
increased.   9 
EBV genome variation and its role in disease 10 
In addition to genetic susceptibility of the host, it is possible that genetic variability in the EBV 11 
genome may play a role in the pathogenesis of severe EBV infection. 12 
The genome of EBV is approximately 184kb long, formed of linear double-stranded DNA.  Following 13 
primary infection, EBV persists in B-cells as an episome and does not normally integrate into the 14 
human genome, although aberrant EBV integration events are seen in some EBV-positive cancers 15 
Raab-Traub 2007).  Genetically and phenotypically, there are two types of EBV (1 and 2) and these 16 
types have different geographic distributions.  EBV type 1 is most prevalent and occurs worldwide, 17 
while EBV type 2 seropositivity shows widespread geographic variation and is reported in 20-25% of 18 
EBV seropositive individuals in parts of Africa and Melanesia (Young et al. 1987), and is found at 19 
lower frequencies outside these regions.  Co-infection with EBV type 1 and EBV type 2 is infrequently 20 
detected (Chang et al. 2009).  Recombinant strains between EBV type 1 and EBV type 2 have been 21 
also reported (Burrows et al. 1996). 22 
EBV type 2 transforms B-cells more poorly than EBV type 1, and there is some in vivo evidence that 23 
type 2 EBV transforms T-cells more successfully than B-cells (Coleman et al. 2015).  There are other 24 
patterns of diversity across individual EBV genes, but they do not lead to such clear patterns of 25 
genome differentiation as the type 1/type 2 distinction (Palser et al. 2015).  26 
The number of EBV genome sequences from healthy individuals is very small and there are few EBV 27 
genome sequences from patients with EBV-specific susceptibilities. Identifying disease-associated 28 
viral variants will require more EBV sequences from pathogenic infections, with age and location 29 
matched controls. 30 
Primary Immune Deficiencies associated with severe EBV disease 1 
Herpesvirus infections are particularly problematic for patients with monogenic defects of the 2 
immune system, and severe or persistent EBV infection is a hallmark combined or innate primary 3 
immunodeficiency.  Among these diverse disorders there is a subset of conditions which appear to 4 
have a particular susceptibility to developing pathogenic consequences of EBV infection, and these 5 
are summarised below.  Interestingly these disorders share a number of functional immune defects 6 
including cytotoxicity, T-cell receptor signalling, effective antibody production, cell migration and 7 
regulation of apoptosis (table 3).  Additionally several patients with combined immunodeficiency 8 
have chronic asymptomatic EBV viraemia.  Optimal management of these patients is unknown, 9 
however careful long term monitoring is essential. 10 
Investigation of patients presenting with severe or atypical EBV infection should focus on early 11 
identification of a possible PID or characterisation of an HLH or CAEBV clinical state.  Detailed 12 
phenotyping of T-  and B-cell differentiation, and functional assays including cytotoxic granule 13 
release and cytotoxic cell killing assays, provide a useful screen for PID and primary HLH, allowing 14 
targeted protein expression assay and genetic sequencing, and guide the bioinformatics of next 15 
generation sequencing data.  A multidisciplinary approach including malignant Haematologists, 16 
Rheumatologists, Infectious Diseases physicians and Clinical Geneticist is recommended.  A proposed 17 
investigation algorithm is shown in figure 3. 18 
X-linked Lymphoproliferative Disease (XLP) / SAP deficiency 19 
XLP-1 is a primary immunodeficiency whose clinical features include HLH, lymphoma and 20 
dysgammaglobulinaemia. (Seemayer et al. 1995; Sumegi et al. 2000; Booth et al. 2011).  Overall 21 
mortality has reduced over time but HLH still remains fatal in the majority of patients with this 22 
manifestation (Booth et al. 2011).  XLP results from mutations in the SH2D1A gene which encodes 23 
the SLAM-associated protein (SAP).  SAP is an intracellular adaptor molecule expressed in T-, NK- and 24 
NKT-cells, and is a key regulator of normal immune function.  Immune defects described in XLP 25 
patients include reduced or absent NKT-cells (Nunez-Cruz et al. 2008), abnormal NK- and CD8+ T-cell 26 
cytotoxicity (Parolini et al. 2000; Tangye et al. 2000; Dupre et al. 2005) and compromised 27 
reactivation induced cell death, all of which could explain the abnormal response to viral infection 28 
(Snow et al. 2009).  Defective CD4+ T follicular helper cell function leads to impaired antibody 29 
function, and lack of memory B-cells and long lived plasma cells (Veillette et al. 2008; Crotty et al. 30 
2003; Qi et al. 2008). 31 
Although XLP is associated with an increased susceptibility to severe EBV disease, the finding that up 32 
to 35% of patients are EBV negative at diagnosis supports our understanding of XLP as a disorder of 33 
severe immune dysregulation, with HLH, lymphoma and humoral abnormalities described in EBV 1 
negative patients (Booth et al. 2011).  No significant difference in mortality was seen between EBV 2 
positive and EBV negative patients. 3 
Management relies on appropriate treatment of HLH and lymphoproliferation, with most patients 4 
requiring immunoglobulin replacement therapy.  Rituximab is routinely used to reduce EBV viral load 5 
and manage EBV related complications.  Survival following HSCT is 81% but mortality increases to 6 
50% in patients with HLH.  Survival for un-transplanted patients is reported as 63% but again 7 
outcome is extremely poor in the context of HLH with survival plummeting to 19% (Booth et al. 8 
2011).  A murine model of XLP has been corrected using HSC gene therapy and this approach may 9 
offer, in the future, an alternative treatment strategy for patients lacking a suitable donor for HSCT 10 
(Rivat et al. 2013).   11 
XIAP deficiency 12 
X-linked inhibitor of apoptosis (XIAP) deficiency is caused by mutations in the BIRC4 gene and 13 
although initially described as XLP-2 due to similarities in clinical presentation to boys with SAP 14 
deficiency (Rigaud et al. 2006), it is now recognised as a more complex disorder of immune 15 
dysregulation, with a wide spectrum of clinical manifestations.  XIAP is ubiquitously expressed and 16 
appears to have several roles in immune cells including in NOD-1 and NOD-2 signalling, and 17 
detection of bacterial infection, alongside its anti-apoptotic role (Aguilar and Latour 2015).  Patients 18 
with XIAP deficiency have reduced NKT-cell numbers and lymphocytes demonstrate increased 19 
activation induced cell death (AICD).  NK-cell cytotoxicity is normal (Marsh, Madden, et al. 2010).  20 
Diagnosis can be made through flow cytometric analysis of protein expression and genetic analysis.  21 
A functional assay demonstrating impaired TNFα production in response to NOD2 pathway 22 
stimulation in monocytes has also been described (Ammann et al. 2014). 23 
A number of case series have now been published which confirm the main clinical features as HLH 24 
(frequently recurrent and of a more indolent course than seen in other primary HLH diseases), 25 
splenomegaly, colitis and periodic fevers (Pachlopnik Schmid et al. 2011; Yang et al. 2012; 26 
Speckmann et al. 2013; Aguilar and Latour 2015).  In contrast to XLP patients, lymphoma has not 27 
been reported in patients with XIAP deficiency.  Hypogammaglobulinaemia is also less common (67% 28 
vs 33%) (Pachlopnik Schmid et al. 2011) and has been described subsequent to EBV infection.  29 
Interestingly female carriers may also exhibit symptoms including erythema nodosum and 30 
inflammatory bowel disease (Dziadzio et al. 2015).  The outcome for XIAP patients receiving HSCT 31 
following myeloablative conditioning is poor with historical data reporting a survival of 14% (Marsh 32 
et al. 2013).  In most cases mortality was due to transplant related toxicity, highlighting the 33 
sensitivity of these patients to drug side effects, likely related to the loss of XIAP’s anti-apoptotic 1 
function.  Results are more favourable with RIC; survival increases to 55% overall, and 86% if 2 
patients are in remission from HLH at the time of transplant.  Minimal intensity conditioning using 3 
anti-CD45 monoclonal antibodies has also been successfully employed (Worth et al. 2013). 4 
ITK deficiency 5 
Interleukin-2 inducible T-cell kinase (ITK) is another recently described autosomal recessive PID 6 
associated with EBV-driven LPD, Hodgkin lymphoma and, more unusually, non-Hodgkin lymphoma 7 
(Huck et al. 2009; Serwas et al. 2014; Mansouri et al. 2012; Stepensky et al. 2011; Linka et al. 2012).  8 
ITK is a member of the TEC kinase family (which includes BTK) and is required for normal 9 
development and signalling in lymphoid cells.  Progressive reduction in CD4+ T-cells, naïve CD4+ T-10 
cells and NKT-cell numbers is a common feature along with hypogammaglobulinaemia.  Clinical 11 
features are primarily related to EBV associated lymphoproliferation but opportunistic infections 12 
associated with T-cell deficiencies have also been reported.  9 patients have been described to date, 13 
8 presenting with LPD between the ages of 3 and 13 years (Ghosh et al. 2014).  6 patients have died 14 
with 5 succumbing within 2 years of presentation despite treatment, demonstrating the devastating 15 
course of this condition.  Fever and lymphadenopathy were found in all patients, with 16 
hepatosplenomegaly and lung involvement in 5/8 symptomatic individuals.  The presence of 17 
autoimmunity in 3, and HLH in 2 suggests an underlying immune dysregulatory component to this 18 
disease but all patients so far have been EBV+ at diagnosis making it difficult to dissect out the role 19 
of EBV.  ITK deficiency can be diagnosed by immunoblot to detect protein expression, with 20 
confirmatory sequence analysis.  The response to chemotherapy treatment of malignancy is 21 
variable.  Some benefit has been shown for rituximab and aciclovir therapy, but steroids do not 22 
appear to ameliorate the clinical features (Ghosh et al. 2014; Cipe et al. 2015).  Two patients have 23 
received HSCT (1 MSD, 1 haploidentical donor) with one patient surviving (Ghosh et al. 2014).  The 24 
optimal management strategy for patients with ITK deficiency is yet to be determined but close 25 
monitoring is essential. 26 
CD27 deficiency 27 
CD27 deficiency is a diagnosis to consider in patients with severe EBV disease, 28 
hypogammaglobulinaemia and recurrent infection.  It is inherited in an autosomal recessive fashion.  29 
As an increasing number of cases are reported, our understanding of the clinical spectrum of this 30 
disease is improving.  CD27 is a co-stimulatory molecule important for the development T, B and NK-31 
cells, in particular memory B-cells.  As CD27 is a widely used marker in the analysis of B- and T-cell 32 
differentiation, flow cytometry offers a simple and reliable screen for this disorder, through 33 
assessing CD27 expression across B-, T- and NK-cells.  All proven CD27 deficient patients have either 1 
absent CD27 expression (9/11 tested) or severely reduced expression (2/11) (Alkhairy et al. 2015).  2 
Reduced numbers of NKT-cells have been reported in severely affected individuals but impaired NK-3 
cell function may be a more consistent immunological finding (Alkhairy et al. 2015).  Impaired T-cell 4 
dependent B-cell responses due to defective CD4+ T-cell help lead to compromised cellular and 5 
humoral immunity, and patients may be misdiagnosed with CVID (van Montfrans et al. 2012).  To 6 
date 17 patients have been described and it is apparent that the clinical phenotype is variable, 7 
ranging from asymptomatic absence of memory B-cells and hypogammaglobulinaema, to EBV driven 8 
HLH and LPD, with no genotype-phenotype correlation (van Montfrans et al. 2012; Salzer et al. 2013; 9 
Alkhairy et al. 2015).  Median age at presentation of symptomatic patients was 6 years in this cohort 10 
(range 1-22 years) with a reported mortality of 29% (Alkhairy et al. 2015).  Many patients received 11 
immunoglobulin replacement therapy, rituximab and appropriate lymphoma treatment.  Three 12 
patients underwent RIC mismatched unrelated cord blood transplant and are alive with the longest 13 
follow up of 4.5 years.  Close monitoring of asymptomatic patients is crucial to allow early 14 
intervention in EBV driven disease.  15 
XMEN (X-linked, magnesium defect, EBV, neoplasia) 16 
XMEN is a recently described serious PID caused by mutations in the MAGT1 gene, encoding the 17 
magnesium transporter 1 protein (Li et al. 2011; Li et al. 2014).  It is characterised by chronic EBV 18 
infection with high viral loads, and increased susceptibility to lymphoma and LPD.  To date 8 patients 19 
have been described with an age at diagnosis of 3-58 years (Ravell, Chaigne-Delalande, and Lenardo 20 
2014; Dhalla et al. 2015).  None have developed HLH or other overt features of immune 21 
dysregulation, unlike the other X-linked lymphoproliferative disorders.  A decreased CD4:CD8 ratio is 22 
a consistent finding with abnormal TCR signalling, but significant humoral defects have not been 23 
described (Li et al. 2014).  Due to abnormal magnesium flux in NK and T-cells, viral specific cytotoxic 24 
cells fail to sufficiently control EBV infection.  Patients also develop other viral infections such as 25 
Molluscum, HSV and VZV, and recurrent sinopulmonary infections (Ravell, Chaigne-Delalande, and 26 
Lenardo 2014).  Haematological malignancy is reported in all post-pubertal patients described, with 27 
many experiencing LPD early in life.  Recurrent malignancy is described in 2 patients. 28 
Two patients received HSCT at the ages of 23 and 45 years but both died in the early post-transplant 29 
period from transplant related complications (Li et al. 2014).  There is a suggestion from in vitro data, 30 
and use in 2 patients, that oral magnesium supplementation can increase NK-cell cytolytic activity 31 
and EBV control.  Although highly experimental, it appears safe and well tolerated (Chaigne-32 
Delalande et al. 2013). 33 
STK4 Deficiency 1 
Serine threonine kinase 4 (STK4) (also known as MST1) deficiency is an autosomal recessive 2 
combined immunodeficiency, characterised by progressive CD4+ lymphopenia.  STK4 is a 3 
ubiquitously expressed constituent of the HIPPO signalling pathway, which regulates cell 4 
proliferation, migration and apoptosis (Zhao, Tumaneng, and Guan 2011).  Specifically, in human 5 
immune cells STK4 plays a critical role in preventing lymphocyte apoptosis (Abdollahpour et al. 2012; 6 
Nehme et al. 2012), thymic egression (Tang et al. 2015) and leucocyte migration (Dang et al. 2016).   7 
13 patients with STK4 deficiency are reported in the published literature (Nehme et al. 2012; Halacli 8 
et al. 2015; Crequer et al. 2012; Abdollahpour et al. 2012; Dang et al. 2016).  Combining these 9 
patients with our experience of 3 unpublished cases (16 in total), 13 patients have been exposed to 10 
EBV, and 11 have developed chronic viraemia.  5 patients have developed EBV driven 11 
lymphoproliferation or malignancy at a median follow up of 11 years of age.  Additionally, these 12 
patients have recurrent invasive bacterial infections, severe cutaneous viral infections, 13 
mucocutaneous candidiasis and autoimmune cytopenias.  In some kindred, intermittent neutropenia 14 
and congenital cardiac defects have been described.  7 patients have been treated by HSCT.  4 15 
patients died of a combination of infectious, toxicity related and GVHD complications, the remaining 16 
3 patients are alive and well, and apparently cured of their immunodeficiency (Nehme et al. 2012; 17 
Dang et al. 2016). 18 
CTP synthetase 1 (CTPS1) Deficiency 19 
CTPS1 deficiency has been recently described in 8 patients, as an autosomal recessive combined 20 
immunodeficiency, caused by a defect in lymphocyte proliferation following antigen receptor 21 
stimulation (Martin et al. 2014).  CTP synthesis contributes to the free cellular CTP pool, essential for 22 
efficient cell division.  CTPS1 activity is induced following TCR activation, and deficiency results in a T-23 
cell proliferative defect despite normal TCR activation signalling.  Clinically, these patients are 24 
susceptible to severe viral infections, and capsulated bacterial infection, suggesting both a functional 25 
defect of T-cell cytotoxicity and T-independent B-cell immunity.  The clinical penetrance of 26 
immunodeficiency appears high, with the majority of patients presenting within the first 2 years of 27 
life.  All patients developed chronic EBV viraemia, with 4/8 patients developing severe IM and 3/8 28 
developing CNS LPD.  6 patients received an HSCT and 4 remain alive, well, and free of symptoms. 29 
Coronin 1A Deficiency 30 
Coronin 1A deficiency was originally described as a thymic egress defect causing T- B+ NK+ severe 31 
combined immunodeficiency (SCID)(Shiow et al. 2008).  Like other immunodeficiencies caused by 32 
actin cytoskeletal defects, Coronin 1A deficiency impacts on a wide range of lymphocyte processes, 33 
including development, survival, TCR signalling, immune synapse formation and migration (Foger et 1 
al. 2006; Punwani et al. 2015; Mace and Orange 2014; Mugnier et al. 2008).  Impaired calcium flux 2 
and f-actin accumulation at the immune synapse, result in increased T-cell apoptosis, compounding 3 
the CD4+ lymphopenia.  A total of 9 patients have been described with Coronin 1A deficiency (Shiow 4 
et al. 2008; Moshous et al. 2013; Mace and Orange 2014; Stray-Pedersen et al. 2014; Punwani et al. 5 
2015; Yee et al. 2016), the majority with a typical SCID clinical presentation.  Patients have an 6 
immunophenotype of absent or low naïve T-cells, severely impaired T proliferative responses, 7 
normal levels of total immunoglobulins, and impaired (but not absent) vaccine responses.  Unlike 8 
other forms of SCID, Coronin 1A deficient patient have normal volume thymic tissue.  5/9 patients 9 
have developed EBV driven B-cell lymphomas, and generally these have been at an earlier age than 10 
in other susceptible PIDs, with 4/5 patients developing EBV-driven LPD prior to 15 months of age.  2 11 
patients died of their lymphomas prior to HSCT.  No patients have developed HLH or severe IM.  3 12 
patients to date have been treated with HSCT.  1 is alive and well, but 2 died following HSCT (GVHD, 13 
relapsed diffuse large B-cell lymphoma).  14 
Activated Phosphatidylinositide 3-Kinase delta syndrome (APDS) 15 
Gain of function mutations in the phosphatidylinositide 3-kinase delta (PI3Kδ) subunit p110δ cause a 16 
combined immunodeficiency of variable clinical severity, characterised by recurrent sino-pulmonary 17 
infections, increased susceptibility to viral infections, lymphoproliferation, bronchiectasis and an 18 
autosomal dominance inheritance pattern (Angulo et al. 2013; Lucas et al. 2014).  PI3Kδ is involved 19 
in downstream signalling from T- and B-cell antigen receptors, costimulatory receptors, cytokine 20 
receptors and some Toll-like receptors (Okkenhaug 2013).  Unregulated activity results in 21 
hyperactivation of the Akt-mTOR pathway, inducing excessive terminal differentiation of effector 22 
lymphocytes, increased activation induced cell death in T-cells, impaired cytokine production and 23 
impaired immunoglobulin class switching in B-cells (Angulo et al. 2013; Lucas et al. 2014).    Although 24 
neither haemophagocytic syndrome nor severe IM have been described in APDS, a high incidence of 25 
chronic EBV viraemia has been described (Kannan et al. 2015; Lucas et al. 2014).  Of 43 patients with 26 
APDS described in the literature, 9 (21%) have developed haematological malignancy or LPD, of 27 
which 3 were EBV positive, and two were undefined (Crank et al. 2014; Angulo et al. 2013; Kannan et 28 
al. 2015; Lucas et al. 2014; Kracker et al. 2014; Hartman et al. 2015).  There is one published patient 29 
who has been successfully treated by HSCT and we have transplanted a second patient without 30 
complication (unpublished).  Inhibition of mTOR activity with Rapamycin has been used to 31 
successfully ameliorate the disease and has improved the immunophenotype in patients (Lucas et al. 32 
2014).  With the availability of selective PI3Kδ inhibitors, pharmacological blockade offers an 33 
attractive line of treatment for these patients. 34 
Radiosensitive SCID 1 
Defects of the non-homologous DNA end joining mechanism result in T- B- NK+ SCID, but clinical 2 
severity of defects in this pathway are heterogeneous, with several patients described with a 3 
hypomorphic phenotype.  Hypomorphic DNA ligase IV and Artemis gene mutations demonstrate 4 
susceptibility for EBV driven-LPD or diffuse large B-cell lymphoma, however HLH has not been seen 5 
(Woodbine, Gennery, and Jeggo 2014; Moshous et al. 2003; Toita et al. 2007; Enders et al. 2006).  6 
Although numbers are small for each of these conditions, the incidence of EBV LPD seems to be 7 
between 20-50% of described patients. 8 
Ataxia Telangectasia (AT) 9 
AT is an autosomal recessively inherited syndrome characterised by progressive cerebellar ataxia, 10 
oculomotor dyspraxia, oculocutaneous telangiectasia, immunodeficiency and susceptibility to 11 
malignancy.  It is caused by mutations in the protein ATM, which plays an integral role in DNA repair 12 
and cell cycle checkpoint control.  A recently published French registry study demonstrated a 19.1% 13 
incidence of lymphoma in patients with AT by 20 years of age.  Approximately 1/3rd of these 14 
lymphomas were Hodgkin Diseases (all tested were EBV related) and 2/3rds were NHL (50% EBV 15 
positive) (Suarez et al. 2015).  HLH, SIM or chronic EBV viraemia has not been described in AT. 16 
CD16 deficiency and other NK defects 17 
Although only 3 patients have been described with homozygous mutation in the gene coding for 18 
CD16, two have developed EBV related severe complications (prolonged IM (de Vries et al. 1996), 19 
EBV-associated B-LPD (Grier et al. 2012)).  Patients have normal numbers of NK-cells, but impaired 20 
NK-cell cytotoxicity, and affected patients suffered from severe viral infections (particularly VZV and 21 
HPV in addition to EBV).  Other monogenic disorders of NK cells (GATA2 and MCM4 deficiencies) also 22 
demonstrate specific EBV susceptibility, and are summarised in table 3 (Spinner et al. 2014; Gineau 23 
et al. 2012; Hughes et al. 2012). 24 
Other Primary Immunodeficiencies with EBV susceptibility 25 
Although all diseases with impaired T-cell function or number will struggle to respond appropriately 26 
to EBV infection, there are several other PIDs which, whilst not having the high penetrance of EBV-27 
associated disease of the above conditions, still frequently develop significant EBV pathology.  28 
Patients with Wiskott Aldrich Syndrome are at high risk of developing malignancy, particularly EBV-29 
driven B-cell lymphoma.  Historical data suggests that without HSCT, over 10% of patients will 30 
develop malignancy with a median age of onset of 9.5 years (Sullivan et al. 1994).  There are also 31 
occasional cases of EBV-driven HLH in Wiskott Aldrich Syndrome (Pasic, Micic, and Kuzmanovic 2003; 32 
Bode et al. 2015).  Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of impaired 33 
lymphocyte apoptosis. There is a linear risk of developing lymphoma with age, and at 30 years 15% 1 
of patients have developed lymphoma, with almost all being EBV positive (Price et al. 2014).  Two 2 
patients have also developed HLH (Bode et al. 2015).  WHIM (Warts, Hypogammaglobulinaemia, 3 
Immunodeficiency and Myelocathexis syndrome) is characterised by a susceptibility to severe 4 
papilloma virus and herpesvirus infections.  Two cases of EBV-associated LPD (fatal in one case) have 5 
been described (Chae, Ertle, and Tharp 2001; Imashuku et al. 2002). 6 
Conclusions and Future Directions 7 
Significant advances in recent years have increased our understanding of the host-virus interaction 8 
in EBV infection and better characterised the pathophysiology of severe and aberrant EBV infection.  9 
We remain, however, far from truly appreciating the complexities of genetically determined 10 
susceptibility to pathological EBV-associated states.  Treatment of these rare disorders, however, 11 
remains inconsistent and optimal therapeutic approaches are largely unknown.  Ongoing 12 
identification of new monogenic PIDs with specific EBV-susceptibility, and further characterisation of 13 
the phenotype and natural history of already described conditions, will aid management strategies 14 
for these patients.  For patients without a discernible immunodeficiency, biomarkers to predict 15 
severe disease progression and those patients who would benefit from early HSCT are urgently 16 
needed.  With improving understanding of the pathophysiology of these conditions, identification of 17 
targeted biologic, cellular or small molecule therapies offers the best hope of managing these 18 
patients effectively and safely in the future.  19 
  20 
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Figure Legends 1 
Figure 1: The Epstein-Barr virus life cycle 2 
Following initial infection (typically through saliva) EBV establish a biphasic life cycle within the host, 3 
allowing non-productive genome maintenance in situations of immune surveillance, termed the 4 
latent cycle, and reactivating to the productive, infectious lytic cycle when in situations of primary 5 
infection or immune suppression.  EBV induces different stages of latency ( in B cells of different 6 
differentiation states, with progressively less viral protein and RNA production as B cells become 7 
more differentiated / less activated.  Individuals with chronic active EBV or other EBV genetic 8 
susceptibilities may be unable to mount an effective CTL or antibody response to lytically replicating 9 
EBV-positive cells, leading to high virus loads and constitutive immune activation.  Abbreviations: 10 
VCA – Viral caspid antigen, EA- Early antigens, EBER – EBV encoded small RNAs, EBNA – EBV nuclear 11 
antigen, LMP – Latent membrane protein, Tfh – T follicular helper cell. 12 
 13 
Figure 2: Clinical manifestations of EBV infection 14 
Although the vast majority of EBV infected individuals have an asymptomatic or self limiting primary 15 
infection (infectious mononucleosis), rare individuals develop more severe clinical syndrome as a 16 
consequence of an impaired ability to control lytic or latent EBV infection, or a the establishment of 17 
latent EBV infection in aberrant (non-B-cell) types.  These complications can be immune 18 
dysregulatory, leading to lymphproliferation and a local or systemic hyperinflammatory state, or 19 
they can be malignant.  Increasingly it appears that these pathologies are closely linked, with 20 
dysregulated inflammatory responses driving EBV-induced malignant proliferation.  As a consequent 21 
there is considerable overlap between many of the malignant and inflammatory EBV clinical 22 
syndromes.  The relationship between these main syndromes is shown in the figure.  Arrows 23 
represent clinical overlap or progression between individual clinical syndromes. 24 
 25 
Figure 3: Clinical investigation algorithm for chronic or pathological EBV infection 26 
We advocate an aggressive approach to the investigation of chronic EBV viraemia and pathological 27 
consequences of EBV infection.  Establishing the detailed immune state of the host, and the 28 
pathophysiology of infection, facilitates close monitoring of patients, assists targeting therapies, and 29 
helps identify which patients may benefit from early stem cell transplant.  The above algorithm 30 
provides an exhaustive list of investigation for patients presenting with EBV – associated 31 
haemophagocytic syndromes, CAEBV, chronic EBV viraemia, SIM, and EBV-driven malignancy.  It 32 
provides a framework for selecting investigations according to an individual patient’s clinical 1 
presentation and disease progress.  We do not propose that every patient should undergo every 2 
investigation listed above.  Management and assessment of these patients benefits from a 3 
multidisciplinary approach involving haematologists, immunologists, rheumatologist, Infectious 4 
diseases specialists, and specialist immunodeficiency and molecular genetics laboratory services.  5 
Abbreviations: TRECs – T-cell recombination excision circles, IgGAME – IgG, IgA, IgM, IgE, DHR - 6 
dihydrorhodamine assay, NBT - nitroblue tetrazolium assay, EM – electron microscope, FBC – full 7 
blood count, LDH – Lactose dehydrogenase, sCD25 – soluble CD25, PID – Primary Immunodeficiency 8 
, fHLH – familial HLH, WES – whole exone sequencing, WGS – whole genome sequencing, ANA – 9 
antinuclear antigen autoantibody, dsDNA – double stranded DNA autoantibody, ENA – Extractable 10 
nuclear antigen autoantibodies, Urinary alb:creat – urinary albumin : creatinine ratio, CMV – 11 
cytomegalovirus, HSV – Herpes simplex virus 1 and 2, VZV – varicella zoster virus, HHV6/7 – Human 12 
herpes virus 6 and 7, HIv – human immunodeficiency virus, BM – bone marrow, VCA – Viral caspid 13 
antigen, EA- Early antigens, EBER – EBV encoded small RNAs, EBNA – EBV nuclear antigen 14 
 15 
Table 1: Genetic disorders associated with primary HLH 
Condition Gene Protein Normal function Diagnosis 
Familial HLH  
 FHL1 Unknown Unknown Unknown Abnormal degranulation assay 
 FHL2 PRF1 Perforin Pore formation Abnormal perforin expression, gene sequencing 
 FHL3 UNC13D Munc 13-4 Vesicle priming Abnormal degranulation assay, gene sequencing 
 FHL4 STX11 Syntaxin 11 Vesicle fusion Abnormal degranulation assay, gene sequencing 
 FHL5 STXBP2 Munc 18-3 Vesicle fusion Abnormal degranulation assay, gene sequencing 
      
X-linked lymphoproliferative disorders 
 XLP SH2D1A SAP Signalling molecule Abnormal SAP expression, gene sequencing 
 XIAP deficiency BIRC4 XIAP Signalling molecule Abnormal XIAP expression, gene sequencing 
     
HLH with pigmentary dilution 
 Chediak Higashi  LYST LYST Vesicle trafficking Hair shaft microscopy, abnormal degranulation 
assay, giant granules in several cell types, gene 
sequencing 
 Griscelli Type 2 RAB27A RAB27A Vesicle docking Hair shaft microscopy, abnormal degranulation 
assay, gene sequencing 
 Hermanksy-Pudlak type 2 AP3B1 AP3B1 Vesicle trafficking Abnormal degranulation assay, gene sequencing 
     
Other causes of HLH with primary immunodeficiency 
 ITK deficiency ITK ITK Signalling molecule Abnormal ITK expression, gene sequencing 
 CD27 deficiency CD27 CD27 Co-stimulatory 
molecule 
Abnormal CD27 expression, gene sequencing 
 APDS PIK3CD PI(3)K 
p100δ 
Signalling molecule Gene sequencing 
 SCID ILR2G, RAG-1  T cell development Abnormal protein expression, gene sequencing 
 DiGeorge Syndrome Chromosome 
 22q11 deletion 
T cell development CGH microarray 
 Wiskott Aldrich Syndrome WASP WASp Various, including 
Vesicle trafficking 
Abnormal protein expression, gene sequencing 
 Chronic Granulomatous 
Disease 
CYBB, NCF1, 
NCF2 
p91-phox, 
p47-phox, 
p67-phox 
Oxidative burst Abnormal DHR/NBT assay, abnormal protein 
expression, gene sequencing 
 
Table 1: Causes of primary HLH and other Primary Immunodeficiencies with HLH as a clinical feature.  FHL -  Familial haemophagocytic 
Lymphohistiocytosis syndrome,  XLP - X-linked lymphoproliferative disease, SAP - SLAM associated protein, XIAP -  X-linked inhibitor of apoptosis, ITK -  IL-2 
inducible T-cell kinase deficiency, XMEN - X-linked immunodeficiency with magnesium defect, APDS - activated PI3kinase delta syndrome, SCID - severe 
combined immunodeficiency, DHR - dihydrorhodamine assay, NBT - nitroblue tetrazolium assay. 
  
Table 2: Comparison of diagnostic criteria for HLH and CAEBV 
Haemphagocytic Histiocytosis Chronic Active Epstein Barr Infection 
Clinical definition requires ≥ 5/8 of criteria below; Persistent illness lasting > 6 months either; 
 Following primary EBV infection or 
 Associated with significantly increased EBV viraemia demonstrated by 
 marked elevation of blood EBV DNA by PCR 
 Significant rise in IgG antibody titres to; 
 VCA (≥ 1:5120) or EA (≥ 1:640) 
Fever 
Splenomegaly 
Cytopenias (affecting ≥2 of 3 lineages in peripheral blood) 
 Haemoglobin <9g/dL (<10g/dl if under 4 weeks of age) 
 Platelets <100 x109/L 
 Neutrophils <1.0 x109/l 
Some or all of the following clinical features (present in ≥ 10% patients); 
 Fever 
 Hepatomegaly and / or splenomegaly 
 Excessive lymphadenopathy 
 Hepatitis 
 Cytopenia 
 Skin rash 
 Hypersensitivity to mosquito bites 
 Hydroa vacciniforme 
Hypertriglyceridaemia and/or hypofibrinogenaemia 
 Fasting triglycerides ≥3.0mmol/L 
 Fibrinogen ≤1.5g/L 
Haemophagocytosis in bone marrow or spleen or lymph node with 
no evidence of malignancy 
Tissue infiltration with lymphocytes (e.g. lymph nodes, bone marrow, liver, skin, 
lung, eye, CNS) 
Low or absent NK cell activity Increased EBV in infiltrated tissues demonstrated by; 
 In situ hybridisation for EBER 
 EBV DNA positivity by PCR 
 EBV protein positivity by immunohistochemistry 
Ferritin >500µg/L 
Soluble CD25 (IL-2 receptor) >2400 U/ml 
If a molecular diagnosis consistent with HLH is confirmed (see 
table 1) then full clinical criteria do not need to be fulfilled 
Absence of any primary or secondary immunodeficiency, or other pathological 
cause of symptoms 
Table 2:  Diagnostic criteria for Haemophagocytic Lymphohistiocytosis (HLH) (Henter et al. 2007) and Chronic active EBV infection (CAEBV) (Kimura et al. 
2001; Kimura et al. 2003; Cohen et al. 2011).  Definitions for CAEBV vary slightly between different studies (duration of symptoms 3-6 months, neccesary 
criteria for EBV viraemia and tissue based disease).  EBER – Epstein Barr Virus-encoded RNA, VCA – viral capsid antigen, EA – Early antigen.   
Table 3  Clinical and Immunopathology of Primary Immunodeficiencies associated with Complex EBV infection 
 Clinical Manifestation Immune Function Pathophysiology 
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XLP              
XIAP def              
ITK def              
CD27 def              
XMEN              
STK4 def              
CTPS1 def              
Coronin1A              
APDS              
RS-SCID              
AT              
CD16 def              
GATA2 def              
MCM4 def              
WAS              
ALPS              
WHIM              
 
Clinical Manifestation  Immune Function  Pathophysiology 
 Frequency  Severity  Severity 
 >75% patients  Full defect  Confirmed defect in humans 
 25 – 75% patients  Severe defect  Predicted / animal model suggestive 
 <25% patients  Partial defect  No defect / Unknown 
 Sporadic cases  Mild defect  
 Not described  No defect 
 
Table 3 Clinical and Immunopathology of Primary Immunodeficiencies associated with Complex EBV infection: HLH - Haemophagocytic lymphohistiocytosis, 
IM – infectious mononucleosis, TCR – T-cell receptor, XLP – X-linked lymphoproliferative syndrome, XIAP – X-linked incativatory of apoptosis, ITK - IL-2 
inducible T-cell kinase deficiency, XMEN - X-linked immunodeficiency with magnesium defect, STK4 – Serine threonine kinase 4, CTPS1 – Cytosine 
triphosphate synthetase 4, APDS - activated PI3kinase delta syndrome, RS-SCID – Radiosensitive severe combined immunodeficiency, AT – Ataxia 
telangectasia, WAS – Wiskott Aldrich Syndromw, ALPS – Autoimmune lymphoproliferative syndromw, WHIM – Warts, hypogammaglobulinaemia, 
immunodeficiency and myelocathexisis syndrome.  % frequencies of clinical manifestations, and severity of immune function defect are based on the 
author’s review of all published case reports of each disease, experience of cases at the authors’ host department, and discussions with other expert 
centres. 
 
  
 
 
 
